Yueyang Changling Equipment Research Institute (China)

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial

VCT220 is a novel nonpeptide, orally available glucagon-like peptide-1 receptor agonist (GLP-1RA) designed to reduce the complex administration of injectable GLP-1RAs and the limited bioavailability of on-marketing oral agents for obesity care. We conducted a multicenter, randomi...

Engineered DynamicCo2+ Sites Resolve theComplete Reaction Network for C(sp3)–H Oxidation

Abstract The dynamic evolution of active sites under operating conditions fundamentally dictates catalytic performance, yet state-of-the-art studies remain confined to passive observation, i.e., they are unable to intervene in detrimental dynamics or translate beneficial ones int...